Clinical Trial Search

Primary: The Concentration of the Pancreatic Cancer Markers of the Normal Cohort and UICC Stage II Pancreatic Ductal Adenocarcinoma Cohort — 99097; 34095 pg/ml — p=<0.001

Primary: Total DNA Yield of Adenocarcinoma — 5930.10; 3365.22 ng/µL — p=0.01

Primary: Survival in Patients With Pancreatic Adenocarcinoma According to Tissue microRNA Expression — 8.3 months

Primary: Diagnostic Yield of Capillary Technique — 75.4 percentage of specimen

Primary: Is the Acquire Needle Non-inferior Compared to SharkCore Needle in Histologic Yield of the Sample Obtained? — 3; 4; 10; 14 Lesions

Primary: Number of Study Participants With Adequate Percutaneous Lavage Specimen Collection — 70; 2; 4 Participants

Primary: SUVmax (Maximal Standard Uptake Value) Measurement 30 and 90 Min p.i. (Post Injection) — 0.77; 0.78; 0.81; 0.8 SUVmax — p=0.78

Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants

Primary: Sensitivity of [68Ga]FAPI-46 PET Imaging to Detect PDAC, Using Histopathology as Truth Standard — 0.741 proportion of participants

Primary: Volume of Aspirated Cyst Fluid as a Function of Estimated Maximal Volume — 78; 74; 73 percentage of cyst volume aspirated — p=0.84

Primary: Survival — 37; 31 participants

Primary: Sensitivity — 59 percentage of participants

Primary: Compare Adequacy of Diagnoses in Passes With and Without a Stylet — 80; 68; 21; 18 passes

Primary: Correlation Between the Growth Speeds of the Cultured Cells and the AJCC TNM Stage (7th Eds) at Entering of the Study. — 21; 29; 14; 9 participants — p=< 0.005

Primary: Diagnostic Yield of EUS-FNB and EUS-FNA — 67.1; 90 percentage of patients

Primary: Number of Patients With Treatment Related Serious Adverse Events — 0; 1; 0 Participants

Primary: Deoxyhemoglobin Concentration (DHb) — .6968475; .3483283; .7021826; .4945491 alpha units — p=0.001

Primary: To Determine the Sensitivity High Resolution Magnetic Resonance Imaging With Lymphotrophic Superparamagnetic Nanoparticles to Identify Small and Otherwise Undetectable…

Primary: Median Number of Passes to Establish Diagnosis — 1; 1 No. of passes

Primary: Comparison of Diagnostic Adequacy Scores With SST vs. CST for Cytologic Diagnosis Using a 22G Core Needle. — 5; 6; 24; 24 Participants

Primary: Overall Survival — 13.43; 7.62 months

Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 7; 16 participants

Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants

Primary: Number of Patients Where TraceIT Tissue Marker Placement Achieved — 6 Participants

Primary: Change From Baseline in Summed Standardized Uptake Value (SUVmax) of Lesion After 2 Cycles of Chemotherapy — 27.45 percentage of SUV Max change

Primary: Diagnostic Accuracy — 237; 263 Participants

Primary: S-MRCP and S-EUS Concordance

Primary: Percentage of Participants Without Disease Progression (Progression-Free Survival) at 6 Months — 78.6; 30 percentage of participants

Primary: Biochemical Response Rate — 383; 550; 43; 53 U/mL

Primary: Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 3; 9 Participants